drug
tofacitinib citrate ER
Marketedupdated 3mo agoby Biocon Pharma Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval120 co-mentions · 60 sources
- drugTOFACITINIB CITRATE111 co-mentions · 60 sources
- drugXELJANZ XR111 co-mentions · 60 sources
- drugXELJANZ111 co-mentions · 60 sources
- drugtofacitinib60 co-mentions · 60 sources
- tagSmall Molecule60 co-mentions · 60 sources
- drugtofacitinib ER60 co-mentions · 60 sources
- companyAjanta Pharma Ltd7 co-mentions · 7 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and psoriatic arthritis and 4 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
all catalysts(32)
approval · 32
Feb 23, 2016
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Aug 22, 2017
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Aug 22, 2017
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Dec 14, 2017
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Aug 17, 2018
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Oct 18, 2018
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Jul 25, 2019
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Aug 30, 2019
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Dec 12, 2019
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Sep 25, 2020
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Jun 1, 2021
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Dec 2, 2021
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Dec 2, 2021
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Dec 14, 2021
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Dec 14, 2021
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
May 14, 2024
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
May 14, 2024
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Sep 27, 2024
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Sep 27, 2024
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Feb 21, 2025
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Feb 21, 2025
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Sep 30, 2025
approval
$SIGY0.04000.00%
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Oct 16, 2025
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Nov 17, 2025
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Feb 18, 2026
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Feb 18, 2026
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Feb 18, 2026
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Feb 18, 2026
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Feb 18, 2026
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Mar 6, 2026
approval
$PFE26.61-0.73%
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Mar 6, 2026
approval
$PFE26.61-0.73%
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Mar 20, 2026
approval
TOFACITINIB CITRATE — FDA approval
tofacitinib citrate ER
→
Trials studying tofacitinib citrate ER
- phase2A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
- phase2Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
- phase2Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 21, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Sep 14, 2034patentUS 10639309*PED
- Sep 14, 2034patentUS 11253523*PED
- Sep 14, 2034patentUS 11253523*PED
- Sep 14, 2034patentUS 9937181*PED
- Mar 14, 2034formulationUS 10639309
- Mar 14, 2034method-of-use (U-3329)US 11253523
- Mar 14, 2034method-of-use (U-3329)US 11253523
- Mar 14, 2034formulationUS 9937181
- Jun 8, 2026patentUS RE41783*PED
- Jun 8, 2026patentUS RE41783*PED
- Jun 8, 2026patentUS RE41783*PED
- Jun 8, 2026patentUS RE41783*PED
- Jun 8, 2026patentUS RE41783*PED
- Dec 8, 2025compositionUS RE41783
- Dec 8, 2025compositionUS RE41783
- Dec 8, 2025compositionUS RE41783
- Dec 8, 2025compositionUS RE41783
- Dec 8, 2025compositionUS RE41783
FDA exclusivities (4)
- Aug 21, 2028PEDPediatric (6mo bonus)2.0y
- Aug 21, 2028PEDPediatric (6mo bonus)2.0y
- Feb 21, 2028M-14Method (3y)1.5y
- Feb 21, 2028M-14Method (3y)1.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that